Principal Business Development Manager

Lab automation ROI hinges on integration, not instrument sensitivity claims. At ADLM 2026, Waters and LabCollector delivered a clear message for lab leaders: the limiting factor in automation is often integration, not hardware. Waters introduced the Xevo TQ Absolute XR IVD mass spectrometer and is positioning it at "5x greater sensitivity" versus in-class instruments, according to SelectScience, but that advantage only carries through if sample prep, calibration and QA, middleware rules, and LIMS result review can keep pace. In parallel, LabCollector announced an AI Co-Scientist feature set for natural-language search, knowledge retrieval, and AI-assisted content creation inside ELN and LIMS workflows, also reported by SelectScience, shifting attention from pipetting speed to retrieval, approval, permissions, and versioning in systems that sit on the documentation path. The Scientist's overview of semi-automated versus fully automated approaches reinforces the point: labs can automate in modules, but they have to run automation as one system. This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership. By MarketScale Newsroom · September 3, 2026, 5:37 AM PDT · Lab Automation Clinical Laboratory Lims Eln Learn this in 60 seconds Key facts, context, and what it means, in one minute. Key takeaways The bottleneck in automation is often the handoff, instrument to middleware to LIMS, so sensitivity and throughput gains depend on interfaces and downstream review as much as the instrument spec. Waters' "5x greater sensitivity" positioning and LabCollector's AI Co-Scientist both point to integration work, sample prep, calibration and QA, middleware rules, and LIMS result review, as the gating factor for ROI. As ELN/LIMS add conversational search and AI-assisted content creation, speed gains move from pipetting to retrieval, approval, permissions, and versioning inside systems that sit in regulated or audited workflows. Get featured Want to get featured in MarketScale Sciences? Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required. The new bottleneck in lab automation is often the handoff, instrument to middleware to LIMS, not the robot arm. Waters introduced the Xevo TQ Absolute XR IVD mass spectrometer at ADLM 2026, and SelectScience reported the company is positioning it at "5x greater sensitivity" versus in-class instruments. That kind of headline spec only matters if the lab's workflow can preserve it, sample prep, calibration and QA, middleware rules, and LIMS result review. ADLM 2026 is putting performance claims back on the table, but the workflow owns the outcome. SelectScience's ADLM coverage also highlighted Roche's view that automation, standardization, and core-lab integration are key to expanding access to mass spectrometry-based testing, framed around making LC-MS/MS more routine rather than more "expert-only." For clinical lab directors and health system procurement teams, the question is whether the lab's full chain of custody can preserve any sensitivity advantage through to the LIS/LIMS result. Sample prep and collection volume constraints, calibration and QA, pre-analytical variability, instrument scheduling, middleware rules, and downstream data review time can all eat the gain. Sensitivity claims still matter for acceptance testing and method validation, but they force an integration decision. If the install plan does not include the interfaces and the SOP rewrites, the "5x" lives on a slide. ELN and LIMS are becoming the control plane for automation. LabCollector's AI Co-Scientist announcement is a different kind of automation news: it is about compressing the time between a question and an actionable answer inside the systems where labs already document work. SelectScience reported the feature set is designed for conversational interaction with laboratory knowledge and for generating scientific content directly within LabCollector's ELN and LIMS workflows. Automation ROI is increasingly limited by retrieval and approval inside ELN and LIMS systems, not only by pipetting speed. When staff can pull prior protocols, reagent history, instrument notes, or the last deviation resolution without digging through folders and PDFs, cycle time can drop even if the physical workflow stays semi-automated. In regulated or audited environments, AI-assisted text generation inside an ELN puts permissions, review, and versioning in the critical path. Labs will need to decide where generated content is allowed, how it is flagged and reviewed, and how it is version-controlled in the audit trail, because the ELN is where procedures and results live. Semi-automation still wins on adoption speed, and the gap shows up in integration work. The Scientist's explainer on lab automation lays out why semi-automated workflows remain common: cost, equipment availability, and the need to tailor automation to application-specific requirements. The article describes how labs often automate a single repetitive task with liquid handling while keeping complex steps manual, an approach that saves time and reduces error without demanding a fully hands-off line. That adoption path is still the default in many organizations, and it intersects with the 2026 product news in a useful way. If the lab is going to stay semi-automated for the next budget cycle, the most durable investments are often the ones that reduce friction at the seams: standardized naming, barcoding discipline, instrument connectivity, and LIMS configuration that can absorb new assays and new instruments without a replatform. SelectScience's product news on Beckman Coulter's DxI 9000 Immunoassay Analyzer points in the same direction. The company said it is expanding infectious disease serology on DxI 9000 to support earlier detection through sensitive and efficient serology testing. The release is light on chemistry specifics, but it is heavy on a familiar operational theme: expanding menus and running them efficiently on existing platforms. That is exactly the kind of change that exposes whether the lab's middleware rules, QC processes, and data review steps are ready. Where this lands in lab budgets: interface work, validation time, and vendor accountability. For enterprise operators, the near-term spend is likely to tilt toward the connective tissue around automation. That includes LIS/LIMS interfaces, instrument drivers, audit trails, and the time to validate and train, especially when new AI capabilities are introduced into systems that already sit in the documentation path. The practical tell is whether a lab is writing requirements that treat the LIMS and the instrument as separate projects. ADLM's 2026 product messages, from Waters' performance framing to LabCollector's conversational ELN/LIMS features, suggest vendors are increasingly selling the workflow, even when they ship a box. Use this checklist to pressure-test whether vendors are selling a workflow, or shipping a box. * For new mass spec installs: what, exactly, is the comparator set behind "in-class" for sensitivity claims, and what acceptance tests will be run on your matrices and volumes, not a demo sample? (Waters' "5x" positioning was reported by SelectScience.) * For ELN/LIMS AI features: where does the model retrieve knowledge from inside your environment, what is the permission model, and how will generated content be flagged, reviewed, and version-controlled in the audit trail? (LabCollector's AI Co-Scientist capabilities were reported by SelectScience.) * For assay or menu expansions on existing analyzers: what middleware, QC, and reporting configuration changes are required, and who owns the validation workload and timeline? (Beckman Coulter's DxI 9000 infectious disease serology expansion was reported by SelectScience.) * For semi-automated workflows you plan to keep: which manual steps are staying manual because of true technical complexity, and which are manual because integration work has been deferred? (The semi-automated versus fully automated distinction is described by The Scientist.) Featured companies Your experts belong here Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find. Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

LetsGetChecked powered by Fuze Health has launched the Onclarity HPV Self-Collection Kit in the US, which it describes as the most comprehensive FDA-cleared at-home HPV cervical cancer screening tool currently available. The kit uses the BD Onclarity HPV Assay, which detects 14 high-risk HPV genotypes and identifies six individual genotypes. According to the National Cancer Institute, roughly one in four women in the US are not up to date with cervical cancer screening. The at-home testing aims to address barriers including logistical challenges, concerns about the screening experience, and limited awareness of options. LetsGetChecked previously received FDA De Novo authorisation in 2023 for an at-home chlamydia and gonorrhea sample collection system. The company has over 13 years of experience delivering at-home screening programmes.